Glenmark Pharmaceuticals Inc., USA, a unit of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), is poised to launch its 8.4% sodium bicarbonate injection and begin its distribution this month, according to a Tuesday filing to the Indian stock exchanges.

The injection is bioequivalent and therapeutically equivalent to Abbott Laboratories Pharmaceutical Products Division's reference listed drug, 8.4% Sodium Bicarbonate Injection.

As per IQVIA's sales data for the 12-month period ended August, the 8.4% Sodium Bicarbonate Injection recorded annual sales of around $63.8 million.

The company's shares were down nearly 2% in recent trade.